Robert Debernardo

1.1k total citations
49 papers, 565 citations indexed

About

Robert Debernardo is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Robert Debernardo has authored 49 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Reproductive Medicine, 35 papers in Surgery and 13 papers in Obstetrics and Gynecology. Recurrent topics in Robert Debernardo's work include Ovarian cancer diagnosis and treatment (36 papers), Intraperitoneal and Appendiceal Malignancies (29 papers) and Endometrial and Cervical Cancer Treatments (10 papers). Robert Debernardo is often cited by papers focused on Ovarian cancer diagnosis and treatment (36 papers), Intraperitoneal and Appendiceal Malignancies (29 papers) and Endometrial and Cervical Cancer Treatments (10 papers). Robert Debernardo collaborates with scholars based in United States, United Kingdom and Australia. Robert Debernardo's co-authors include Laura Chambers, Chad M. Michener, Peter G. Rose, Meng Yao, Haider Mahdi, Sarah Goodrich, David Lockhart, Mehdi Kebria, Roberto Vargas and Anna Chichura and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Obstetrics and Gynecology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Robert Debernardo

46 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Debernardo United States 14 277 262 121 116 66 49 565
Meng Yao United States 12 181 0.7× 182 0.7× 59 0.5× 129 1.1× 46 0.7× 87 449
Anne Van Arsdale United States 12 121 0.4× 116 0.4× 183 1.5× 148 1.3× 120 1.8× 25 588
Tim Mould United Kingdom 17 398 1.4× 126 0.5× 171 1.4× 483 4.2× 163 2.5× 48 980
Linda Hertlein Germany 10 173 0.6× 77 0.3× 67 0.6× 113 1.0× 59 0.9× 18 378
Monica Hagan Vetter United States 11 173 0.6× 91 0.3× 62 0.5× 225 1.9× 27 0.4× 33 480
Ulaş Solmaz Türkiye 15 195 0.7× 144 0.5× 59 0.5× 322 2.8× 14 0.2× 55 632
İlker Kahramanoğlu Türkiye 15 242 0.9× 129 0.5× 82 0.7× 301 2.6× 40 0.6× 65 568
Rony A. Adam United States 11 113 0.4× 181 0.7× 48 0.4× 93 0.8× 33 0.5× 33 476
Jason A. Lachance United States 13 178 0.6× 117 0.4× 104 0.9× 223 1.9× 21 0.3× 18 442
Charlotte Burmeister United States 14 96 0.3× 110 0.4× 86 0.7× 171 1.5× 35 0.5× 46 456

Countries citing papers authored by Robert Debernardo

Since Specialization
Citations

This map shows the geographic impact of Robert Debernardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Debernardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Debernardo more than expected).

Fields of papers citing papers by Robert Debernardo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Debernardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Debernardo. The network helps show where Robert Debernardo may publish in the future.

Co-authorship network of co-authors of Robert Debernardo

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Debernardo. A scholar is included among the top collaborators of Robert Debernardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Debernardo. Robert Debernardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Müller, Carolin, et al.. (2024). Feasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease. International Journal of Gynecological Cancer. 35(1). 100010–100010.
2.
3.
4.
Lampert, Erika J., Peter G. Rose, Robert Debernardo, et al.. (2023). Association of Clinical Trial Participation With Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer. Obstetrical & Gynecological Survey. 78(11). 648–649.
5.
Michener, Chad M., Stephanie Ricci, Mariam AlHilli, et al.. (2023). Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3. Gynecologic Oncology. 178. 102–109. 2 indexed citations
6.
Debernardo, Robert, et al.. (2023). Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Cancers. 15(5). 1402–1402. 13 indexed citations
7.
8.
9.
Yao, Meng, Michelle Kuznicki, Roberto Vargas, et al.. (2022). Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer. Gynecologic Oncology. 165(1). 90–96. 7 indexed citations
10.
Chambers, Laura, Meng Yao, Anna Chichura, et al.. (2021). Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. Gynecologic Oncology. 162(3). 645–651. 11 indexed citations
11.
Dey, Goutam, Caner Saygin, Daniel J. Silver, et al.. (2021). Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors. Journal of Ovarian Research. 14(1). 55–55. 9 indexed citations
12.
Chambers, Laura, Meng Yao, Anna Chichura, et al.. (2021). Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecologic Oncology. 162(2). 368–374. 25 indexed citations
13.
Chichura, Anna, Laura Chambers, Meng Yao, et al.. (2021). Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. Gynecologic Oncology. 161(1). 194–201. 9 indexed citations
14.
Chambers, Laura, Meng Yao, Anna Chichura, et al.. (2021). Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. International Journal of Gynecological Cancer. 31(7). 1021–1030. 6 indexed citations
15.
Chambers, Laura, Michelle Kuznicki, Max Horowitz, et al.. (2020). A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecologic Oncology. 158(3). 794–802. 25 indexed citations
16.
Debernardo, Robert, et al.. (2017). Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer. Anti-Cancer Drugs. 28(7). 815–817. 14 indexed citations
17.
Mahdi, Haider, Sarah Goodrich, David Lockhart, Robert Debernardo, & Mehdi Kebria. (2014). Predictors of Surgical Site Infection in Women Undergoing Hysterectomy for Benign Gynecologic Disease: A Multicenter Analysis Using the National Surgical Quality Improvement Program Data. Journal of Minimally Invasive Gynecology. 21(5). 901–909. 75 indexed citations
18.
Armstrong, Amy J., Balint Otvos, Sareena Singh, & Robert Debernardo. (2013). Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer. Gynecologic Oncology. 131(3). 503–507. 23 indexed citations
19.
Gruenigen, Vivian E. von, Heidi E. Frasure, Deborah A. Smith, et al.. (2012). Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies. Anti-Cancer Drugs. 23(7). 724–730. 5 indexed citations
20.
Debernardo, Robert, et al.. (1999). An E-Mail Assessment of Undergraduates' Attitudes Toward Smoking. Journal of American College Health. 48(2). 61–66. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meng Yao Breakdown of academic impact, for papers by Anne Van Arsdale Breakdown of academic impact, for papers by Tim Mould Breakdown of academic impact, for papers by Linda Hertlein Breakdown of academic impact, for papers by Monica Hagan Vetter Breakdown of academic impact, for papers by Ulaş Solmaz Breakdown of academic impact, for papers by İlker Kahramanoğlu Breakdown of academic impact, for papers by Rony A. Adam Breakdown of academic impact, for papers by Jason A. Lachance Breakdown of academic impact, for papers by Charlotte Burmeister
Rankless by CCL
2026